KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) Interest & Investment Income (2018 - 2026)

Castle Biosciences' Interest & Investment Income history spans 8 years, with the latest figure at $2.9 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 14.12% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.8 million, a 8.86% decrease, with the full-year FY2025 number at $11.8 million, down 8.86% from a year prior.
  • Interest & Investment Income hit $2.9 million in Q4 2025 for Castle Biosciences, up from $2.8 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CSTL hit a ceiling of $3.4 million in Q3 2024 and a floor of $4000.0 in Q1 2021.
  • Historically, Interest & Investment Income has averaged $2.0 million across 5 years, with a median of $2.6 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: plummeted 98.66% in 2021 and later soared 13282.35% in 2022.
  • Tracing CSTL's Interest & Investment Income over 5 years: stood at $17000.0 in 2021, then soared by 13282.35% to $2.3 million in 2022, then skyrocketed by 37.1% to $3.1 million in 2023, then grew by 8.11% to $3.4 million in 2024, then fell by 14.12% to $2.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for CSTL at $2.9 million in Q4 2025, $2.8 million in Q3 2025, and $2.9 million in Q2 2025.